Click here to learn more!
| This week's FierceBiotech is brought to you by IQVIA.
Trouble viewing? Click here. |
|
| In a recent Phase III bipolar disorder trial, our customer set an aggressive timeline to meet an NDA filing window. IQVIA accelerated site identification and patient recruitment to help our customer achieve this milestone. |
|
| IQVIA Core-Powered Clinical Development. |
|
| Our CORE-powered approach to clinical development dramatically increases speed and efficiency to help you bring your products to patients faster. |
Proof, not promises.
|
|
| Data based on a recent Phase III bipolar disorder trial. Comparisons based on previous studies in the same indication and geographies conducted by IQVIA. Results may vary due to various factors. |
| Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact [email protected] or call 202-824-5074.
About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe. Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400
Washington, DC 20036 |
